First pill for high cholesterol on the market – for whom it is suitable
Home Knowledge As of 26/08/2026, 11:59 PM Comments We follow on Google New cholesterol drug on the market: US authority allows Lipfendra. ©..
- Center-left1
- Center-right1
1 agency rewrite / co-publication detected
Summary
In clinical trials, it lowered LDL cholesterol by 56 to 59 percent compared to placebo. In July 2026, the FDA approved Lipfendra, the trade name of Enlicitid, the first PCSK9 inhibitor to be taken once a day as a tablet.
Cross-referenced from 2 sources.
Factual coreconfirmed by several independent voices
Insufficient core: not enough independent confirmations to retain a shared fact.
Reported detailssecondary facts, each attributed to its source
In clinical trials, it lowered LDL cholesterol by 56 to 59 percent compared to placebo.
according to Frankfurter Rundschau +1In July 2026, the FDA approved Lipfendra, the trade name of Enlicitid, the first PCSK9 inhibitor to be taken once a day as a tablet.
according to Frankfurter Rundschau +1
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.
Sources2 sources cross-checked
Center-left1
Center-right1
